{"nctId":"NCT03527732","briefTitle":"Efficacy and Safety of IVM/ALB Co-administration","startDateStruct":{"date":"2018-09-09","type":"ACTUAL"},"conditions":["Trichuriasis"],"count":1673,"armGroups":[{"label":"Arm A: albendazole","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Albendazole"]},{"label":"Arm B: albendazole and ivermectin","type":"EXPERIMENTAL","interventionNames":["Drug: Albendazole and Ivermectin"]}],"interventions":[{"name":"Albendazole","otherNames":["Zentel®"]},{"name":"Albendazole and Ivermectin","otherNames":["Zentel® and Stromectol®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written informed consent signed by either the participant him/herself (≥21 years of age) or by parents and/or caregivers for children/adolescents; and written assent by child/adolescent (aged 6-20 years).\n2. Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and on three follow-up assessments (approximately 3 weeks, 6 months, and 12 months later).\n3. Aged ≥6 to \\<= 60 years for parallel group trial and ≥6 to \\<=12 years for DF study.\n4. At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 100 EPG.\n\nExclusion Criteria:\n\n1. No written informed consent by individual/parents and/or caregiver.\n2. Presence of major systemic illnesses, e.g. severe anemia (below 80 g/l Hb according to WHO \\[28\\]), clinical malaria as assessed by a medical doctor (positive Plasmodium RDT and ≥38 °C ear temperature), upon initial clinical assessment.\n3. History of acute or severe chronic disease (e.g. cancer, diabetes, chronic heart, liver or renal disease).\n4. Recent use of anthelmintic drug (within past 4 weeks).\n5. Attending other clinical trials during the study.\n6. Negative or low egg count (less than 100 EPG or less than 2 out of 4 slides positive) diagnostic result for T. trichiura eggs in the stool.\n7. Known allergy to study medications (i.e. albendazole and ivermectin).\n8. Pregnancy or lactating in the 1st week after birth (according to WHO guidelines within LF control programs \\[29\\]).\n9. Currently taking medication with known interaction (e.g. for albendazole: cimetidine, praziquantel and dexamethasone; for ivermectin: warfarin).","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured)","description":"The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"140","spread":null},{"groupId":"OG004","value":"18","spread":null},{"groupId":"OG005","value":"140","spread":null}]},{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"200","spread":null},{"groupId":"OG002","value":"178","spread":null},{"groupId":"OG003","value":"73","spread":null},{"groupId":"OG004","value":"275","spread":null},{"groupId":"OG005","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) After 6 and 12 Months Post Treatment","description":"Conversion of T. trichiura egg-positive participants at baseline who become egg-negative 6 and 12 months after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"154","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"154","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Egg-reduction Rate (ERR) Against T. Trichiura","description":"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"57","spread":null},{"groupId":"OG005","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"79.6","spread":null},{"groupId":"OG003","value":"99.0","spread":null},{"groupId":"OG004","value":"21.2","spread":null},{"groupId":"OG005","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"91.3","spread":null},{"groupId":"OG003","value":"99.6","spread":null},{"groupId":"OG004","value":"53.6","spread":null},{"groupId":"OG005","value":"92.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Concomitant Soil-transmitted Helminth Infections Egg Negative Post-Treatment (Cured)","description":"Number of participants that converted from egg positive with Ascaris lumbricoides, hookworm and/or Strongyloides stercoralis infections to egg negative after 14-21 days. Number of egg-negatives at 6 and 12 months after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"70","spread":null},{"groupId":"OG004","value":"68","spread":null},{"groupId":"OG005","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"172","spread":null},{"groupId":"OG003","value":"184","spread":null},{"groupId":"OG004","value":"205","spread":null},{"groupId":"OG005","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"166","spread":null},{"groupId":"OG003","value":"170","spread":null},{"groupId":"OG004","value":"60","spread":null},{"groupId":"OG005","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"115","spread":null},{"groupId":"OG004","value":"40","spread":null},{"groupId":"OG005","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"111","spread":null},{"groupId":"OG003","value":"117","spread":null},{"groupId":"OG004","value":"262","spread":null},{"groupId":"OG005","value":"262","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"126","spread":null},{"groupId":"OG003","value":"146","spread":null},{"groupId":"OG004","value":"250","spread":null},{"groupId":"OG005","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Egg-reduction Rates (ERRs) Against Concomitant Soil-transmitted Helminth Infections.","description":"Percent change in geometric mean eggs per gram of stool from before to after treatment. ERRs will be calculated for Ascaris lumbricoides and hookworm infections as described in outcome 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"82.2","spread":null},{"groupId":"OG003","value":"75.8","spread":null},{"groupId":"OG004","value":"-5.7","spread":null},{"groupId":"OG005","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"87.3","spread":null},{"groupId":"OG003","value":"77.0","spread":null},{"groupId":"OG004","value":"25.0","spread":null},{"groupId":"OG005","value":"48.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"99","spread":null},{"groupId":"OG005","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"96.6","spread":null},{"groupId":"OG003","value":"97.7","spread":null},{"groupId":"OG004","value":"72.2","spread":null},{"groupId":"OG005","value":"73.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"98.8","spread":null},{"groupId":"OG003","value":"99.2","spread":null},{"groupId":"OG004","value":"74.5","spread":null},{"groupId":"OG005","value":"59.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":254},"commonTop":["Headache","Abdominal pain","Itching","Diarrhea","Nausea"]}}}